These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3920064)

  • 61. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synthesis, absolute configuration, and conformation of the aldose reductase inhibitor sorbinil.
    Sarges R; Bordner J; Dominy BW; Peterson MJ; Whipple EB
    J Med Chem; 1985 Nov; 28(11):1716-20. PubMed ID: 3934383
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.
    Cameron NE; Leonard MB; Ross IS; Whiting PH
    Diabetologia; 1986 Mar; 29(3):168-74. PubMed ID: 3084324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Applicability of red blood cell sorbitol measurements to monitor the clinical activity of sorbinil.
    Peterson MJ; Page MG; Just LJ; Aldinger CE; Malone JI
    Metabolism; 1986 Apr; 35(4 Suppl 1):93-5. PubMed ID: 3515121
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effects of sorbinil on the pathophysiology of diabetic complications. Proceedings of a symposium. Dorado, Puerto Rico, May 30-June 2, 1985.
    Metabolism; 1986 Apr; 35(4 Suppl 1):1-121. PubMed ID: 3083196
    [No Abstract]   [Full Text] [Related]  

  • 66. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E; Edelist T; Varagiannis E
    Pharmacology; 1986; 32(1):52-60. PubMed ID: 3080763
    [TBL] [Abstract][Full Text] [Related]  

  • 68. NADPH-oxidising activity in lens and erythrocytes in diabetic and nondiabetic patients with cataract.
    Crabbe MJ; Bron AJ; Peckar CO; Petchey M; Ting HH; Howard-Williams J
    Br J Ophthalmol; 1983 Oct; 67(10):696-9. PubMed ID: 6412739
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
    Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Binding of an aldose reductase inhibitor to renal glomeruli.
    Cohen MP; Klepser H
    Biochem Biophys Res Commun; 1985 Jun; 129(2):530-5. PubMed ID: 3925947
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
    Williams WF; Odom JD
    Science; 1986 Jul; 233(4760):223-5. PubMed ID: 3088727
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modulation of myo-[3H]inositol uptake by glucose and sorbitol in cultured bovine lens epithelial cells. II. Characterization of high- and low-affinity myo-inositol transport sites.
    Cammarata PR; Chen HQ; Yang J; Yorio T
    Invest Ophthalmol Vis Sci; 1992 Dec; 33(13):3572-80. PubMed ID: 1464503
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthesis and biological evaluation of irreversible inhibitors of aldose reductase.
    Ares JJ; Kador PF; Miller DD
    J Med Chem; 1986 Nov; 29(11):2384-9. PubMed ID: 3097318
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function.
    Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optical spectroscopy as an in vitro method to monitor aldose reductase inhibitors in the lens.
    Lerman S; Megaw J; Gardner K
    Invest Ophthalmol Vis Sci; 1983 Nov; 24(11):1505-10. PubMed ID: 6417041
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of aldose reductase and its inhibition on sugar cataract formation.
    Kador PF; Akagi Y; Kinoshita JH
    Metabolism; 1986 Apr; 35(4 Suppl 1):15-9. PubMed ID: 3083204
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Time-dependent aspects of osmolyte changes in rat kidney, urine, blood and lens with sorbinil and galactose feeding.
    Edmands SD; Hughs KS; Lee SY; Meyer SD; Saari E; Yancey PH
    Kidney Int; 1995 Aug; 48(2):344-53. PubMed ID: 7564101
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. Effects of aldose reductase inhibition.
    Willars GB; Calcutt NA; Compton AM; Tomlinson DR; Keen P
    J Neurol Sci; 1989 Jun; 91(1-2):153-64. PubMed ID: 2473171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.